MCID: GLL048
MIFTS: 45

Glial Tumor

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Glial Tumor

MalaCards integrated aliases for Glial Tumor:

Name: Glial Tumor 58
Glioma 58

Characteristics:

Orphanet epidemiological data:

58
glial tumor
Prevalence: 1-9/100000 (United States),1-5/10000 (Europe);

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

MESH via Orphanet 44 D005910
UMLS via Orphanet 72 C0017638
Orphanet 58 ORPHA182067

Summaries for Glial Tumor

MalaCards based summary : Glial Tumor, also known as glioma, is related to childhood brain stem glioma and brain stem glioma. An important gene associated with Glial Tumor is IDH1 (Isocitrate Dehydrogenase (NADP(+)) 1), and among its related pathways/superpathways are Glucose / Energy Metabolism and Central carbon metabolism in cancer. The drugs Midazolam and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial, and related phenotypes are growth/size/body region and respiratory system

Wikipedia : 74 Glial tumor is a general term for numerous tumors of the central nervous system (CNS), including... more...

Related Diseases for Glial Tumor

Diseases related to Glial Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1111)
# Related Disease Score Top Affiliating Genes
1 childhood brain stem glioma 33.8 OLIG2 IDH1
2 brain stem glioma 33.3 PTEN OLIG2 IDH1
3 mixed oligodendroglioma-astrocytoma 32.1 PTEN IDH1
4 glioma susceptibility 1 31.7 PTEN OLIG2 IDH1
5 medulloblastoma 31.2 PTEN MMP9 IDH1
6 glioma 30.4 PTEN MMP9 IDH1
7 dysembryoplastic neuroepithelial tumor 30.2 OLIG2 IDH1
8 arteriovenous malformation 30.1 PTEN MMP9
9 glioblastoma multiforme 30.0 PTEN MMP9 IDH1
10 oligodendroglioma 30.0 PTEN OLIG2 IDH1
11 li-fraumeni syndrome 30.0 PTEN IDH1
12 childhood oligodendroglioma 29.8 OLIG2 IDH1
13 supratentorial cancer 29.8 OLIG2 IDH1
14 high-grade astrocytoma 29.8 PTEN IDH1
15 brain stem cancer 29.7 OLIG2 IDH1
16 central nervous system cancer 29.7 PTEN OLIG2 IDH1
17 brain glioma 29.6 PTEN IDH1
18 hemangioma 29.6 PTEN MMP9 IDH1
19 giant cell glioblastoma 29.6 PTEN OLIG2 IDH1
20 gemistocytic astrocytoma 29.5 PTEN IDH1
21 gliomatosis cerebri 29.5 PTEN IDH1
22 mixed glioma 29.4 PTEN OLIG2 IDH1
23 juvenile pilocytic astrocytoma 29.4 PTEN OLIG2 IDH1
24 clear cell ependymoma 29.4 OLIG2 IDH1
25 supratentorial primitive neuroectodermal tumor 29.4 OLIG2 IDH1
26 skin melanoma 29.4 PTEN MMP9
27 brain cancer 29.4 PTEN OLIG2 IDH1
28 grade iii astrocytoma 29.3 PTEN OLIG2 MMP9 IDH1
29 leukemia, acute myeloid 29.3 PTEN MMP9 IDH1
30 lung cancer susceptibility 3 29.3 PTEN MMP9 IDH1
31 intrahepatic cholangiocarcinoma 29.3 PTEN MMP9 IDH1
32 fibrillary astrocytoma 29.2 PTEN OLIG2 IDH1
33 benign giant cell tumor 29.2 MMP9 CA2
34 myeloma, multiple 29.1 PTEN MMP9 IDH1
35 myelodysplastic syndrome 29.0 PTEN MMP9 IDH1
36 clear cell renal cell carcinoma 28.9 PTEN MMP9 IDH1
37 gastric adenocarcinoma 28.8 PTEN MMP9 IDH1
38 gliosarcoma 28.8 PTEN OLIG2 MMP9 IDH1
39 spinal disease 28.8 PTEN OLIG2 IDH1
40 osteoporosis 27.7 PTEN MMP9 CA2
41 optic nerve glioma 12.6
42 glioma susceptibility 9 12.6
43 glioma susceptibility 3 12.6
44 optic pathway glioma 12.5
45 glioma susceptibility 2 12.5
46 mixed neuronal-glial tumor 12.5
47 diffuse midline glioma, h3 k27m-mutant 12.4
48 subependymal glioma 12.3
49 glial tumor of neuroepithelial tissue with unknown origin 12.3
50 childhood optic nerve glioma 12.3

Graphical network of the top 20 diseases related to Glial Tumor:



Diseases related to Glial Tumor

Symptoms & Phenotypes for Glial Tumor

MGI Mouse Phenotypes related to Glial Tumor:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.55 CA2 IDH1 MMP9 OLIG2 PTEN
2 respiratory system MP:0005388 9.35 CA2 IDH1 MMP9 OLIG2 PTEN
3 skeleton MP:0005390 9.02 CA2 IDH1 MMP9 OLIG2 PTEN

Drugs & Therapeutics for Glial Tumor

Drugs for Glial Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 559)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
2
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
3
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
4 Anti-Anxiety Agents Phase 4
5 Excitatory Amino Acid Antagonists Phase 4
6 alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Phase 4
7 Anesthetics Phase 4
8 Analgesics, Non-Narcotic Phase 4
9 Analgesics Phase 4
10 Hypnotics and Sedatives Phase 4
11 Adrenergic Agents Phase 4
12 Adrenergic alpha-Agonists Phase 4
13 Adrenergic Agonists Phase 4
14
Dextroamphetamine Approved, Illicit Phase 3 51-64-9 5826
15
Lenograstim Approved, Investigational Phase 3 135968-09-1
16
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
17
Carmustine Approved, Investigational Phase 3 154-93-8 2578
18
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
19
Dalteparin Approved Phase 3 9005-49-6
20
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
21
Somatostatin Approved, Investigational Phase 2, Phase 3 38916-34-6, 51110-01-1 53481605
22
Ondansetron Approved Phase 3 99614-02-5 4595
23
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
24
Trioxsalen Approved Phase 3 3902-71-4 5585
25
Donepezil Approved Phase 3 120014-06-4 3152
26
Thioguanine Approved Phase 3 154-42-7 2723601
27
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
28
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
29
Ethanol Approved Phase 2, Phase 3 64-17-5 702
30
Disulfiram Approved Phase 2, Phase 3 97-77-8 3117
31
Copper Approved, Investigational Phase 2, Phase 3 7440-50-8 27099
32
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
33
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
34
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
35
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
36
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
37
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
38
Etoposide Approved Phase 3 33419-42-0 36462
39
leucovorin Approved Phase 3 58-05-9 6006 143
40
Histamine Approved, Investigational Phase 3 51-45-6 774
41
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
42
Cyproheptadine Approved Phase 3 129-03-3 2913
43
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
44
Norepinephrine Approved Phase 3 51-41-2 439260
45
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
46
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
47
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
48
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
49 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
50 Dianhydrogalactitol Investigational Phase 3 23261-20-3

Interventional clinical trials:

(show top 50) (show all 1444)
# Name Status NCT ID Phase Drugs
1 A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection Completed NCT02193568 Phase 4
2 Phase II Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
3 Seizure Treatment IN Glioma (STING): Comparing a Treatment Strategy With Levetiracetam Versus Treatment With Valproic Acid in Glioma Patients With a First Seizure Recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
4 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
5 Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
6 Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome of Patients Undergoing Brain Tumor Exclusion Recruiting NCT04266665 Phase 4 Dexmedetomidine
7 A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
8 Cognitive Rehabilitation of Glioma Patients: a Prospective, Randomized Study Unknown status NCT00256425 Phase 3
9 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Unknown status NCT01765088 Phase 3 Temozolomide;α-IFN
10 Randomized Controlled Multicenter Trial on the Impact of Presurgical Navigated Transcranial Magnetic Stimulation for Motor Mapping of Rolandic Lesions Unknown status NCT02879682 Phase 3
11 Prospective Randomized Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Pediatric Diffuse Brainstem Glioma Unknown status NCT01878266 Phase 3
12 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
13 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Unknown status NCT02892708 Phase 3
14 A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial Unknown status NCT02363075 Phase 3 Dexamfetamine sulphate;placebo
15 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
16 Barrow 5-ALA Intraoperative Confocal Evaluation Trial Unknown status NCT01502280 Phase 3 5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
17 A Prospective, Randomized, Controlled, Double-blind, Multi-center Clinical Study of Nimotuzumab Combinated With Gemcitabine Contrast to Placebo Combinated With Gemcitabine in K-RAS Wild-type,Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
18 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
19 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
20 A Prospective,Randomized,Double-Blind,Controlled,Multicenter,Phase III Study of Nimotuzumab in Combination With Chemotherapy and Radiotherapy for Patients With Local Advanced Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
21 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
22 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
23 PET/CT Imaging of Malignant Glioma With Somatostatin Analog 68Ga-DOTATOC Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
24 A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma Completed NCT01781468 Phase 3 armodafinil 150 mg;armodafinil 250 mg
25 A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE) Completed NCT00135876 Phase 3 dalteparin
26 Clinical Study to Assess the Positive Predictive Value of NPC-07 Induced Tissue Fluorescence in Patients With Malignant Glioma (WHO Grades III/IV) Completed NCT01167322 Phase 3 NPC-07 for oral administration
27 Prospective Randomized Trial of Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children. Completed NCT01635140 Phase 3
28 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
29 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
30 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
31 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
32 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
33 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
34 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
35 Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
36 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
37 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
38 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
39 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
40 Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
41 PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
42 PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
43 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
44 A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREATMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER Completed NCT00561990 Phase 2, Phase 3 Nimotuzumab
45 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
46 Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial Completed NCT00224978 Phase 3 Chloroquine
47 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
48 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation Recruiting NCT04164901 Phase 3 AG-881;Matching Placebo
49 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene
50 A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy Recruiting NCT02796261 Phase 3 Eflornithine;Lomustine;Lomustine

Search NIH Clinical Center for Glial Tumor

Genetic Tests for Glial Tumor

Anatomical Context for Glial Tumor

MalaCards organs/tissues related to Glial Tumor:

40
Brain, T Cells, Endothelial, Spinal Cord, Testes, Bone, Retina

Publications for Glial Tumor

Articles related to Glial Tumor:

(show top 50) (show all 30470)
# Title Authors PMID Year
1
A novel germline mutation of PTEN associated with brain tumours of multiple lineages. 61 6
12085208 2002
2
Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. 6
16825431 2007
3
Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. 6
15689453 2005
4
Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. 6
14670928 2004
5
Expression of Concern: Ras-AKT signaling represses the phosphorylation of histone H1.5 at threonine 10 via GSK3 to promote the progression of glioma. 61
32180473 2020
6
Natural borneol sensitizes human glioma cells to cisplatin-induced apoptosis by triggering ROS-mediated oxidative damage and regulation of MAPKs and PI3K/AKT pathway. 61
31875760 2020
7
c(RGDyk)-modified nanoparticles encapsulating quantum dots as a stable fluorescence probe for imaging-guided surgical resection of glioma under the auxiliary UTMD. 61
32207347 2020
8
Examination of sulfonamide-based inhibitors of MMP3 using the conditioned media of invasive glioma cells. 61
32156166 2020
9
Sterically stabilized recombined HDL composed of modified apolipoprotein A-I for efficient targeting toward glioma cells. 61
32241173 2020
10
The enhanced treatment efficacy of invasive brain glioma by dual-targeted artemether plus paclitaxel micelles. 61
32524852 2020
11
The enhanced efficacy of herpes simplex virus by lentivirus mediated VP22 and cytosine deaminase gene therapy against glioma. 61
32439343 2020
12
In vivo MRS measurement of 2-hydroxyglutarate in patient-derived IDH-mutant xenograft mouse models versus glioma patients. 61
32003035 2020
13
Label-free discrimination of glioma brain tumors in different stages by surface enhanced Raman scattering. 61
32456910 2020
14
Gomisin J inhibits the glioma progression by inducing apoptosis and reducing HKII-regulated glycolysis. 61
32560813 2020
15
WBSCR22 confers cell survival and predicts poor prognosis in glioma. 61
32380188 2020
16
ST1926 inhibits glioma progression through regulating mitochondrial complex II. 61
32526455 2020
17
Long non-coding RNA TP73-AS1 contributes to glioma tumorigenesis by sponging the miR-103a/GALNT7 pathway. 61
32416102 2020
18
SOX15 exerts antitumor function in glioma by inhibiting cell proliferation and invasion via downregulation of Wnt/β-catenin signaling. 61
32416168 2020
19
The HOTTIP (HOXA transcript at the distal tip) lncRNA: Review of oncogenic roles in human. 61
32335298 2020
20
Impact of Anesthesia on Long-term Outcomes in Patients With Supratentorial High-grade Glioma Undergoing Tumor Resection: A Retrospective Cohort Study. 61
30807485 2020
21
Design, synthesis, DNA binding studies and evaluation of anticancer potential of novel substituted biscarbazole derivatives against human glioma U87 MG cell line. 61
32502918 2020
22
Late Contrast Enhancing Brain Lesions in Proton-Treated Patients With Low-Grade Glioma: Clinical Evidence for Increased Periventricular Sensitivity and Variable RBE. 61
32234554 2020
23
Dequalinium chloride inhibits the growth of human glioma cells in vitro and vivo: a study on molecular mechanism and potential targeted agents. 61
32410120 2020
24
Astragaloside IV suppresses transforming growth factor-β1-induced epithelial-mesenchymal transition through inhibition of Wnt/β-catenin pathway in glioma U251 cells. 61
32154763 2020
25
Temporoinsular Glioma Resection under Awake Mapping: 2-Dimensional Operative Video. 61
31674637 2020
26
Microcystic Macular Edema in Optic Nerve Glioma. 61
32564817 2020
27
Pleomorphic xanthoastrocytoma in the posterior fossa: a case report with advanced neuroimaging findings. 61
32120310 2020
28
Par-4 regulates autophagic cell death in human cancer cells via upregulating p53 and BNIP3. 61
32135176 2020
29
Radiological Recurrence Patterns after Bevacizumab Treatment of Recurrent High-Grade Glioma: A Systematic Review and Meta-Analysis. 61
32524791 2020
30
Advances in circular RNAs and their role in glioma (Review). 61
32319596 2020
31
Repeat Radiation in the Brain: Managing Patients With Locally Recurrent Glioma. 61
32503786 2020
32
Predicting survival using the 2016 World Health Organization classification for anaplastic glioma. 61
32194024 2020
33
Neuregulin 1 enhances cell adhesion molecule L1 like expression levels and promotes malignancy in human glioma. 61
32565959 2020
34
LINC01198 facilitates gliomagenesis through activating PI3K/AKT pathway. 61
32378450 2020
35
Survival among patients with glioma in the US Military Health System: A comparison with patients in the Surveillance, Epidemiology, and End Results program. 61
32286688 2020
36
AVNP2 protects against cognitive impairments induced by C6 glioma by suppressing tumour associated inflammation in rats. 61
32097763 2020
37
Glioblastoma Stem Cell-Derived Exosomes Enhance Stemness and Tumorigenicity of Glioma Cells by Transferring Notch1 Protein. 61
31853695 2020
38
Partners of wild type Grb7 and a mutant lacking its calmodulin-binding domain. 61
32360748 2020
39
Nose-to-brain drug delivery system with ligand/cell-penetrating peptide-modified polymeric nano-micelles for intracerebral gliomas. 61
32387702 2020
40
Targeting of endoplasmic reticulum (ER) stress in gliomas. 61
32305494 2020
41
Letter to the editor regarding anesthesia management for low-grade glioma awake surgery: a European low-grade glioma network survey. 61
32383015 2020
42
Reply to: Letter to the Editor Regarding Anesthesia Management for Low-Grade Glioma Awake Surgery: A European Low-Grade Glioma Network Survey. 61
32388680 2020
43
Hemodynamic investigation of peritumoral impaired blood oxygenation-level dependent cerebrovascular reactivity in patients with diffuse glioma. 61
32302735 2020
44
Differential roles of pyramidal and fast-spiking, GABAergic neurons in the control of glioma cell proliferation. 61
32423877 2020
45
Long non-coding RNA NEAT1 promotes human glioma tumor progression via miR-152-3p/CCT6A pathway. 61
32454145 2020
46
Awake vs. asleep motor mapping for glioma resection: a systematic review and meta-analysis. 61
32388682 2020
47
Abnormal polarization of macrophage-like cells in the peripheral blood of patients with glioma. 61
32566024 2020
48
Commentary: Temporoinsular Glioma Resection Under Awake Mapping: 2-Dimensional Operative Video. 61
31811304 2020
49
The Use of 5-Aminolevulinic Acid in Low-Grade Glioma Resection: A Systematic Review. 61
31828346 2020
50
Target delivering paclitaxel by ferritin heavy chain nanocages for glioma treatment. 61
31838201 2020

Variations for Glial Tumor

ClinVar genetic disease variations for Glial Tumor:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 subset of 188 genes: ELAVL2 , HNRNPK complex Likely pathogenic 617751 9:23524426-87359888

Expression for Glial Tumor

Search GEO for disease gene expression data for Glial Tumor.

Pathways for Glial Tumor

Pathways related to Glial Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.29 PTEN IDH1 CA2
2 10.8 PTEN IDH1

GO Terms for Glial Tumor

Cellular components related to Glial Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ficolin-1-rich granule lumen GO:1904813 8.96 MMP9 IDH1
2 tertiary granule lumen GO:1904724 8.62 MMP9 IDH1

Biological processes related to Glial Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to organic cyclic compound GO:0014070 9.26 PTEN IDH1
2 response to organic substance GO:0010033 9.16 PTEN CA2
3 response to steroid hormone GO:0048545 8.96 IDH1 CA2
4 response to zinc ion GO:0010043 8.62 PTEN CA2

Molecular functions related to Glial Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 8.92 PTEN OLIG2 MMP9 IDH1

Sources for Glial Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....